Theravance Biopharma TBPH Current ratio

Current ratio at other companies

Gyre Therapeutics, Inc.GYRE

4.3×-1.1×

Rigel PharmaceuticalsRIGL

2.6×+0.4×

LQD

Liquidia CorporationLQDA

2.2×-0.7×

Royalty PharmaRPRX

2.8×+1.5×

United TherapeuticsUTHR

5.7×-1.5×

Zevra Therapeutics, Inc.ZVRA

5.2×-2.7×

FAQ

What is Theravance Biopharma's current ratio?

Theravance Biopharma (TBPH) reported current ratio of 13.1× in Q1 2026.

How has Theravance Biopharma's current ratio changed year-over-year?

Theravance Biopharma's current ratio increased by 175.5% year-over-year, from 4.8× to 13.1×.

What is the long-term trend for Theravance Biopharma's current ratio?

Over 5 years (2020 to 2025), Theravance Biopharma's current ratio has grown at a 28.0% compound annual growth rate (CAGR), from 3.2× to 10.9×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.